Infinity Pharmaceuticals (NASDAQ: INFI) novel approach is based on Targeting Immune Suppressive Macrophages by selectively inhibiting PI3K-Gamma. The Company’s lead candidate eganelisib, is a first-in-class, oral, once-daily selective inhibitor of phosphoinositide-3-kinase gamma (PI3K-gamma), that has the potential to transform the immuno-oncology space. IPI-549 has demonstrated...
Aveo Pharmaceuticals, Inc. (NASDAQ: AVEO) was one of our stock picks this week based on its promising pipeline and an impending FDA approval for FOTIVDA® (tivozanib). The Company has scored a big win with its approval, which not only validates its unique approach but also...
Sesen Bio, Inc. (NASDAQ: SESN) is focused on creating targeted fusion protein therapeutics (TFPTs) for treatment of cancers. The Company is looking at a major catalyst in 2021, the approval of Vicineum, a potential best-in-class therapeutic for the treatment of non-muscle invasive bladder cancer (NMIBC)...
Galera Therapeutics (NASDAQ: GRTX), a clinical–stage Biopharmaceutical Company aiming to redefine radiotherapy in cancer, announced positive interim results from a phase 1/2 trial of GC4419 or avasopasem manganese. An investigational, highly selective small molecule superoxide dismutase mimetic, GC4419 has the potential to convert superoxide to...
Cannabics Pharmaceuticals (OTCQB: CNBX), an early-stage Biotechnology Company focussed on creating cannabinoid-based therapeutics and therapies for treatment of cancer, announced the signing of a Memorandum of Understanding (MoU) with RCK Medical Cannabis, an Israeli cannabis company that creates tailor-made medical cannabis strains and hybrid seeds...
Paratek Pharmaceuticals (NASDAQ: PRTK), a commercial-stage biopharmaceutical Company, announced the withdrawal of its submission to the European Medicines Agency (EMA), for the grant of Marketing Authorization Application (MAA) for NUZYRA® (omadacycline). The Company was developing the candidate for two indications namely, acute bacterial skin and...
Adverum Biotechnologies (NASDAQ: ADVM), a clinical-stage Company focused on developing therapeutics for ocular and rare diseases through gene therapy, released additional clinical data from its ongoing OPTIC phase 1 clinical trial of ADVM-022. ADVM-022, the Company’s lead ocular candidate, is an adeno- associated virus (AAV)....
